Xlife Sciences AGXSWX:XLS 53 Debt-to-Equity is 0.21 as of Dec. 2025, which is 25% below its 10-year median of 0.28. GuruFocus rates XSWX:XLS with a GF Score™ of 53/100 and a GF Value™ of CHF7.25 (Significantly Overvalued). The stock has 10 warning signs investors should review. Among 965 Biotechnology companies, Xlife Sciences AG ranks worse than 55.96% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Xlife Sciences AG's Debt-to-Equity or its related term are showing as below:
XSWX:XLS'
s Debt-to-Equity Range Over the Past 10 Years
Min: 0.19 Med: 0.28 Max: 0.62
Current: 0.21
During the past 8 years, the highest Debt-to-Equity Ratio of Xlife Sciences AG was 0.62. The lowest was 0.19. And the median was 0.28.
XSWX:XLS's Debt-to-Equity is ranked worse than 55.96% of 965
companies
in the Biotechnology industry
Industry Median: 0.16
vs XSWX:XLS: 0.21
Xlife Sciences AG (XSWX:XLS) Debt-to-Equity Explanation
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Xlife Sciences AG Debt-to-Equity Related Terms
Xlife Sciences AG Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Xlife Sciences AG's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:XLS vs VRTX, REGN, ALNY: Debt-to-Equity Comparison
For the Biotechnology subindustry, Xlife Sciences AG's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Xlife Sciences AG Debt-to-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Xlife Sciences AG's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Xlife Sciences AG's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Xlife Sciences AG (XSWX:XLS) has a Debt-to-Equity of 0.21 as of Dec. 2025. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Xlife Sciences AG and its competitors. This is 25% below median its historical median of 0.28. Over the past decade, Xlife Sciences AG's Debt-to-Equity has ranged from 0.19 to 0.62. According to the industry distribution chart, Xlife Sciences AG ranks #540 out of 965 companies in the Biotechnology industry, placing it in the top 56%.
Is Xlife Sciences AG's Debt-to-Equity too high?
Xlife Sciences AG's current Debt-to-Equity of 0.21 is 25% below median its 10-year median of 0.28. Over the past 10 years, this metric has ranged from a low of 0.19 to a high of 0.62. The Biotechnology industry median Debt-to-Equity is 0.16. Xlife Sciences AG's value of 0.21 is 31.3% above this industry median. Based on the distribution chart, Xlife Sciences AG ranks #540 out of 965 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Xlife Sciences AG has a GF Score™ of 53/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xlife Sciences AG's Debt-to-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Xlife Sciences AG ranks #540 out of 965 companies for Debt-to-Equity. This places Xlife Sciences AG in the lower half of its industry. The industry median Debt-to-Equity is 0.16. Xlife Sciences AG's value of 0.21 is 31.3% above this benchmark. Historically, Xlife Sciences AG's own Debt-to-Equity has ranged from 0.19 to 0.62 over the past decade. While the company's 10-year median is 0.28 vs. the industry median of 0.16, Xlife Sciences AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 965 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Xlife Sciences AG's current Debt-to-Equity of 0.21 is 31.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Xlife Sciences AG and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Xlife Sciences AG's current Debt-to-Equity is 0.21, which is 25% below median its own 10-year median of 0.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xlife Sciences AG stock overvalued right now?
Based on GuruFocus' analysis, Xlife Sciences AG (XSWX:XLS) is currently considered Significantly Overvalued. The stock's GF Value™ is CHF7.25, compared to a current price of CHF18.15 — trading 150.3% above its estimated fair value. The current Debt-to-Equity is 0.21, which is 25% below median its 10-year median of 0.28 and 31.3% above the Biotechnology industry median of 0.16. Xlife Sciences AG's overall GF Score™ is 53/100 with 10 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Xlife Sciences AG (XSWX:XLS), the current Debt-to-Equity is 0.21 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Xlife Sciences AG (XSWX:XLS) Overvalued in 2026?
Based on GuruFocus' analysis, Xlife Sciences AG stock appears to be overvalued.
The current stock price of CHF18.15 is trading 150.3% above its estimated GF Value™ of CHF7.25.
GuruFocus considers Xlife Sciences AG to be Significantly Overvalued.
Key valuation signals for XSWX:XLS:
Debt-to-Equity: 0.21 (25% below median its 10-year median of 0.28)
GF Value™: CHF7.25 vs. price of CHF18.15 (150.3% above fair value)
Industry Position: 31.3% above the Biotechnology median (#540 of 965)
No single metric tells the full story. See the XSWX:XLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Xlife Sciences AG is a Swiss incubator and accelerator company focused on the value development and commercialization of research projects from universities and other life science research institutions, to provide solutions for high-unmet medical needs. It holds majority or minority interests in project companies that are engaged in areas of the company's reportable segments, which include Technology platforms, Medical Technology, Biotechnology/Therapeutics, and Artificial Intelligence/Digital Medicine.
53GF Score
Get the complete analysis for XSWX:XLS
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:XLS has been successfully added to your 
